Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden-Reference-Cited by-同舟云学术

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden

Published:2010-08-19 Issue:18 Volume:116 Page:4299-4308
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Morschhauser Franck,Mounier Nicolas,Sebban Catherine,Brice Pauline,Solal-Celigny Phillippe,Tilly Herve,Feugier Pierre,Fermé Christophe,Copin Marie Christine,Lamy Thierry

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25280/fullpdf

Reference43 articles.

1. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood.,2005

2. Treatment strategies in follicular lymphomas: current status and future perspectives;Hiddemann;J Clin Oncol.,2005

3. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study;Herold;J Clin Oncol.,2007

4. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study;Salles;Blood.,2008

5. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia;Bellosillo;Blood.,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The investigation and management of follicular lymphoma;British Journal of Haematology;2020-06-24

2. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy;Blood;2019-08-15

3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2018-08

4. A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment;Oncotarget;2017-12-09

5. Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies;The AAPS Journal;2017-02-21